Check Point profits helped by Pointsec purchase

Check Point Software Technologies Ltd., the world's second-largest network security company, said second-quarter profit increased 6% after its purchase of the Pointsec product line boosted sales.

By
July 25, 2007 07:43
2 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Check Point Software Technologies Ltd., the world's second-largest network security company, said second-quarter profit increased 6 percent after its purchase of the Pointsec product line boosted sales. Net income rose to $69.5 million, or 31 cents a share, from $65.7m., or 27 cents, a year earlier, the Redwood City, California-based company said Tuesday. Revenue climbed 27% to $176.2m. from $138.4m. Check Point acquired Pointsec, a maker of data-encryption technology for storing sensitive information on laptops and other mobile devices, when it bought Sweden's Protect Data AB last January. Pointsec was approved as a US Defense Department vendor last week. "The company has made the right moves to stabilize its core business, while Pointsec gives Check Point a leading presence in one of the hottest areas of information technology security," Dino Diana, an analyst at UBS AG, said in a note to investors. Earnings excluding charges climbed to 38 cents a share in the second quarter from 32 cents a year earlier. That compared with the 36 cents median estimate of eight analysts surveyed by Bloomberg News. In April, Check Point forecast earnings of between 26 cents and 31 cents a share on sales of between $166m. and $176m. for the quarter. Shares of Check Point were heading for their biggest gain in two years, trading up $1.53, or 6.5%, at $25.23 late morning in New York. Before Tuesday, the shares had risen 43% in the past year, compared with a 33% gain in the Nasdaq Composite Index. Earnings this year, not counting stock compensation and one-time expenses, will range from $1.48 to $1.58 a share on revenue of between $700m. and $720m., Chief Executive Officer Gil Shwed said on a conference call. A poll of 24 analysts surveyed by Bloomberg before the company's new estimate had forecast earnings of $1.48 on sales of about $707m. Network security products contributed $155.8m. to revenue, up 12% from a year earlier, while Pointsec data security products bought in $20.4m., an increase of 17% from the first quarter, Check Point said. "We believe these efforts are now paying off as we are experiencing healthy growth from our data security business," Vice Chairman Jerry Ungerman said on the conference call, referring to the Protect Data acquisition and new products. Deferred revenue, or orders for which money will be collected in coming quarters, reached $236.2m., a gain of 34% from the same time in 2006. Cash flow from operations fell to $81.5m. from $88.6m. a year earlier. (Bloomberg)

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS